Axxam and Promega announced today formalization of an agreement that will offer world-class early-stage drug discovery services for different classes of targets and cellular pathways.

Global clients will have facilitated access to innovative customized luminescence-based, cell-free and cell-based assays suitable to run in miniaturized and fully automated High-Throughput Screening (HTS) format, in search of novel drug candidates.